BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | Jun 26, 2019
Financial News

Spain’s Sanifit heads to Phase III with €72.2M in new funding

With €72.2 million ($82.1 million) in fresh cash to fund a Phase III study of its lead candidate to treat a rare vascular calcification disorder, Sanifit is looking ahead to additional Phase IIb trial results...
BioCentury | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Mar 9, 2018
Clinical News

Sanifit's SNF472 meets in Phase II for rare vascular calcification syndrome

Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving wound healing from baseline to week 12 as measured by the Bates-Jensen Wound Assessment Tool (BWAT) in a single-arm...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BioCentury | Sep 7, 2017
Emerging Company Profile

Coating calcifications

Inositec AG aims to halt vascular calcification in patients with chronic kidney disease by making analogs of the calcium chelator inositol hexaphosphate that are safer and more drug-like than the natural product. According to co-founder...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Oct 24, 2016
Clinical News

SNF472: Phase II started

Sanifit began an open-label, international Phase II trial to evaluate SNF472 given over 3 months in 15 newly diagnosed patients. Calciphylaxis is a rare condition characterized by vascular calcification and thrombosis leading to necrosis of...
BioCentury | Oct 24, 2016
Finance

Eyes on Spain

Ysios Capital Partners kept the doors open for its second fund longer than expected to welcome a new crop of deep-pocketed LPs who took interest in the firm’s latest investments. Ysios BioFund II Innvierte launched...
Items per page:
1 - 10 of 15
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | Jun 26, 2019
Financial News

Spain’s Sanifit heads to Phase III with €72.2M in new funding

With €72.2 million ($82.1 million) in fresh cash to fund a Phase III study of its lead candidate to treat a rare vascular calcification disorder, Sanifit is looking ahead to additional Phase IIb trial results...
BioCentury | Jul 17, 2018
Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Mar 9, 2018
Clinical News

Sanifit's SNF472 meets in Phase II for rare vascular calcification syndrome

Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving wound healing from baseline to week 12 as measured by the Bates-Jensen Wound Assessment Tool (BWAT) in a single-arm...
BioCentury | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BioCentury | Sep 7, 2017
Emerging Company Profile

Coating calcifications

Inositec AG aims to halt vascular calcification in patients with chronic kidney disease by making analogs of the calcium chelator inositol hexaphosphate that are safer and more drug-like than the natural product. According to co-founder...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Oct 24, 2016
Clinical News

SNF472: Phase II started

Sanifit began an open-label, international Phase II trial to evaluate SNF472 given over 3 months in 15 newly diagnosed patients. Calciphylaxis is a rare condition characterized by vascular calcification and thrombosis leading to necrosis of...
BioCentury | Oct 24, 2016
Finance

Eyes on Spain

Ysios Capital Partners kept the doors open for its second fund longer than expected to welcome a new crop of deep-pocketed LPs who took interest in the firm’s latest investments. Ysios BioFund II Innvierte launched...
Items per page:
1 - 10 of 15